Last update Sept. 19, 2016

Κυπροτερόνη οξική

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Progestogen with antiandrogenic properties that is used for the treatment of conditions with hypersexuality, prostate carcinoma, transsexualism and, together with ethinyl estradiol, for hirsutism, acne and alopecia and hyperandrogenism in women.

It is excreted into breast milk in small quantities (Stoppelli 1980), but their anti-androgenic effects could be clinically significant for the infant when doses of 50 milligrams per day or higher are used.

The small amount (2 mg) contained in contraceptive tablets in which it is combined with ethinyl estradiol would represent a very low risk and would be compatible with breastfeeding.

Alternatives

We do not have alternatives for Κυπροτερόνη οξική.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Κυπροτερόνη οξική is Cyproterone Acetate in Greek.

Is written in other languages:

Group

Κυπροτερόνη οξική belongs to this group or family:

Tradenames

Main tradenames from several countries containing Κυπροτερόνη οξική in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 88 %
Molecular weight 417 daltons
Protein Binding 96 %
Tmax 2 - 3 hours
43 - 50 hours
M/P ratio 1.1 - 9.3 -
Theoretical Dose 0.01 - 0.07 mg/Kg/d
Relative Dose 1.2 - 8.4 %

References

  1. Bayer. Diane. Product Monograph. 2014 Full text (in our servers)
  2. AEMPS. Ciproterona-Etinilestradiol. Ficha técnica. 2013 Full text (in our servers)
  3. AEMPS. Ciproterona. Ficha técnica. 2011 Full text (in our servers)
  4. AA Pharma. Cyproterone. Product Monograph. 2010 Full text (in our servers)
  5. Stoppelli I, Rainer E, Hümpel M. Transfer of cyproterone acetate to the milk of lactating women. Contraception. 1980 Nov;22(5):485-93. Abstract

Total visits

1,326

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM